Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
BACKGROUND: We assessed the utility of the dual PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235) as single agent therapy and in combination with conventional chemotherapy for thyroid cancer.METHODOLOGY/PRINCIPAL FINDINGS: Eight cell lines from four types of thyroid cancer (papillary, follicular, anaplastic, medullary) were studied.The cytotoxicity of BEZ235